Prothena Corp Plc Dossier
Qualitative Analysis
Business overview
Prothena Corporation plc (NASDAQ: PRTA) is a late-stage clinical biotechnology company specializing in protein dysregulation. The company leverages its deep scientific expertise to discover and develop novel therapies aimed aiming at changing the course of devastating neurodegenerative and rare peripheral amyloid diseases. Prothena's robust pipeline includes both wholly-owned programs and high-profile global partnerships with industry leaders such as Roche, Bristol Myers Squibb (BMS), and Novo Nordisk. Key clinical candidates include birtamimab for AL amyloidosis, prasinezumab (partnered with Roche) for Parkinson's disease, coramitug (partnered with Novo Nordisk) for ATTR amyloidosis, and BMS-986446/PRX019 (partnered with BMS) for neurodegenerative diseases.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In June 2025, Prothena initiated a major corporate restructuring, reducing its workforce by approximately 63% to align its operating costs with its strategic focus. This was followed by a planned reduction of an additional 17 employees in early 2026.
Expected impact: Substantially reduces ongoing operating costs, allowing the company to preserve its cash runway to support remaining wholly owned programs, satisfy obligations to partnered programs, and fund business development activities.
Following shareholder approval at an Extraordinary General Meeting in November 2025 to reduce share capital and create distributable reserves (confirmed by the Irish High Court in January 2026), Prothena's Board authorized a Share Repurchase Plan in February 2026.
Expected impact: Aims to return capital to shareholders and leverage the company's strong cash position to take advantage of perceived market undervaluation without compromising R&D funding.
Prothena is actively developing and applying its proprietary CYTOPE technology, which incorporates a cell-internalizing domain to drive efficient cytosolic delivery of macromolecular effectors to target intracellular disease pathways in the brain and periphery.
Expected impact: Expands the company's pipeline into intracellular targets, such as TDP-43 for ALS and frontotemporal lobar degeneration, and enhances the delivery of wholly owned assets like PRX012-TfR for Alzheimer's disease.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Collaborating on the development of prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for the treatment of early-stage Parkinson's disease. Roche initiated the Phase 3 PARAISO trial in Q4 2025.
Terms: To date, Prothena has earned $135 million with up to $620 million in additional milestone payments that include regulatory and sales milestones. In addition, Roche has agreed to pay Prothena up to double-digit teen royalties on net sales.
Collaborating on coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy. Novo Nordisk initiated the Phase 3 CLEOPATTRA trial in Q4 2025.
Terms: Prothena received a $50.0 million milestone payment in Q1 2026 related to the ongoing Phase 3 clinical trial. Prothena is eligible for further clinical, regulatory, and commercial milestones, plus royalties.
Collaborating on BMS-986446 (an anti-MTBR-tau antibody in Phase 2 for Alzheimer's disease) and PRX019 (a potential treatment for neurodegenerative diseases in Phase 1). Bristol Myers Squibb obtained the exclusive global license for PRX019 in 2024.
Terms: Prothena is conducting the Phase 1 trial for PRX019 and is eligible to earn a $55 million clinical milestone payment by the end of 2026 if Bristol Myers Squibb decides to advance the program. Prothena is also eligible for milestones and royalties on BMS-986446.